Benitec Biopharma Q1 net loss widens on higher R&D costs
BNTC•Benitec Biopharma reported a fiscal first-quarter net loss of $12.9 million as research and development expenses increased. It ended the quarter with $176 million in cash and expects to begin a pivotal BB-301 trial in mid-2027.
1. Quarterly results
Benitec Biopharma's fiscal first-quarter net loss widened year over year as research and development expenses increased, driven by ongoing clinical development of BB-301 for OPMD. The company ended the quarter with $176 million in cash and cash equivalents.
2. Trial timeline
Benitec expects to confirm the design of the BB-301 pivotal study in the first calendar quarter of 2027 and is on track to begin the pivotal trial in mid-2027. The company will change its fiscal year-end to Dec. 31 from June 30.
